US 9192570

I'll start by verifying the patent record and checking for any 2026 litigation activity.

Let me verify the claim text and check for any PTAB/Federal Circuit activity involving this specific patent.

Let me pin down the inventor name discrepancy and retrieve the actual claim language.

Search note

I searched for the exact number 9,192,570 (and its US publication US2015/0174061 A1) and for any Federal Circuit / PTAB activity in it. Searches were run against public web sources (Google Patents, an official-copy PDF of the printed patent, PTAB/IPR exhibits, Fed. Cir. opinions, and litigation filings), not a live authenticated USPTO Patent Center or CAFC docket query — so the litigation section below is "nothing found in public sources," not a certified docket clearance. Results for neighboring numbers (e.g., 9,211,253; 9,763,876; 9,289,425; Adapt/Teva's 9,358,509-family and 9,687,454/'305) are not this patent and were excluded.

Bibliographic record — US 9,192,570 B2

Abstract (verbatim): "Disclosed herein are compositions containing an opioid antagonist such as naloxone and one or more pharmaceutically acceptable excipients. The compositions may be used for intranasal delivery of Naloxone for the treatment of, for example, opioid overdose in an individual in need thereof. Also disclosed are methods of making compositions containing Naloxone, and devices for nasal delivery of naloxone compositions."

Plain-language overview of the claims

Important caveat on confidence: I was not able to retrieve the verbatim granted claim set in this session (the full-text feed supplied stopped in the description, and my claim-text queries returned other patents' claims instead). What follows is a reconstruction of the independent claims from the specification's own summary statements, which track claim language, and from the specification's internal cross-reference to "the composition of claim 1." Treat it as high-confidence on substance, medium-confidence on exact wording and claim numbering.

1. Independent composition claim (believed to be claim 1) — A nasal spray/composition comprising, in aqueous carrier:

• about 7–11 mg/mL naloxone or a pharmaceutically acceptable salt (with a specific embodiment at 10 mg/mL naloxone HCl dihydrate, ≈1 mg per 100 µL);
• about 20–30 mM citric acid buffer (e.g., 25 mM);
• about 5–15 mM ethylenediaminetetraacetic acid (EDTA) (e.g., 10 mM disodium EDTA dihydrate);
• about 0.2–1.0% benzyl alcohol as antimicrobial preservative (e.g., 0.5%);
• pH about 3–5.5 (specific embodiment pH 3.5–5.0, target ≈4.25), with NaCl to osmolality ≈385–425 mOsm.
  The specification emphasizes that this composition is substantially free of parabens, hypromellose/cellulose viscoelastic polymers, and other residence-time enhancers (glycerine, propylene glycol, sorbitol), which the inventors found accelerated naloxone degradation; and that it does not form the degradant 7,8-didehydronaloxone.

1. Independent composition claim with pharmacokinetic limitation — A composition as above defined by its in vivo performance, e.g., intranasal administration yielding a Tmax of about 0.1–0.5 h and/or a Cmax of about 1.0–4.0 ng/mL at about 5–30 minutes, and/or AUC0-inf, after a 100 µL or 200 µL dose. (The specification expressly recites "the composition of claim 1 wherein administration … results in a parameter selected from a Tmax of about 0.1 hours to about 0.5 hours …".)

2. Independent method claim — A method of treating/reversing a known or suspected opioid overdose (manifested by respiratory and/or CNS depression) by intranasally administering the disclosed composition, e.g., a unit dose of about 200 µL divided into two ~100 µL half-doses, one per naris, optionally repeated.

3. Independent device claim — A nasal spray device (unit-dose container) containing the disclosed composition, characterized as single-use, needle-free, ready-to-use and/or disposable, delivering about 80–120 µL (≈100 µL) per spray.

4. Independent kit claim — A kit comprising one or more such nasal spray devices (a two-device kit is expressly described), sealed in foil/pouch secondary packaging, optionally with written and/or pictorial instructions (support the head, remove sprayers, one sprayer per nostril, use each sprayer once, call 911, observe for improvement, second set if no improvement).

Dependent claims appear to narrow to sodium chloride/osmolality adjustments, NaOH/HCl pH adjustment, absence of paraben preservatives, absence of hypromellose, the specific 10 mg/mL naloxone HCl dihydrate / 25 mM citric acid / 10 mM EDTA / 0.5% benzyl alcohol formulation, and storage-stability limits.

Litigation, PTAB, and CAFC status

• No Federal Circuit or PTAB proceeding against US 9,192,570 itself was found. I found no 2026 CAFC docket naming this patent.
• This patent appears as prior art, not as the patent-in-suit, in several proceedings:
• Adapt Pharma Operations Ltd. v. Teva Pharmaceuticals USA, Inc., Nos. 20-2106 (Fed. Cir. Feb. 10, 2022) — the opinion and the appellant briefing repeatedly cite "Wyse, U.S. Patent No. 9,192,570, col. 27, ll. 29–44" for the teaching that benzalkonium chloride (BZK) was not acceptable with naloxone ("due to increased observed degradation") and that benzyl alcohol/parabens were used instead.
• IPR2019-00451 (review of US 9,763,876, Opiant) — a scanned copy of US 9,192,570 was filed as Patent Owner Exhibit 2030.
• IPR2019-00685 (review of US 9,211,253, Nalox-1 v. Opiant) — "Wyse" is relied on in the petitioner's declaration for several method limitations.
• EP 3,932,399 A1 (Brittania/alginate opioid-antagonist film) cites "US 9,192,570 B2 — WYSE JOSEPH" in its search report.
• The patent's assignee history overlaps Indivior, but Indivior's publicly reported patent litigation (Suboxone film/tablet ANDA cases, DRL, Alvogen, Actavis, Teva) involves different patents, and Indivior's public reporting does not describe a CAFC 2026 case on the '570 patent.

Uncertainty / discrepancies I want to flag explicitly

1. Inventor name. The patent full text I was given lists "Michael Paul DeHart," and the INPI record for the EP counterpart (EP 3082816) lists "DEHART, Michael, Paul." However, one scanned copy of the printed US front page rendered the second inventor as "Michael Paul Dietter" (possibly an OCR error, possibly a correction in the printed patent). I cannot resolve this authoritatively from the sources available; the second inventor is either DeHart or Dietter, both of Winterville, NC.
2. Verbatim claim text. As noted, I could not pull the exact granted claim language or the exact independent-claim numbering. The overview above is a specification-derived reconstruction. Before relying on claim scope (e.g., for infringement, validity, or FTO work), the claim set should be read directly from the granted patent or USPTO Patent Center.
3. Docket search completeness. I did not execute an authenticated USPTO Patent Center / PTAB API query or a CAFC CM/ECF docket query. "No 2026 CAFC activity found" means none surfaced in public web search, not that none exists.

I'll search for litigation involving US patent 9192570 across patent litigation databases.

Let me search more specifically for litigation asserting this patent and check the litigation databases.

Let me verify the AntiOp v. Reckitt contract case and check whether the '570 patent itself was ever challenged at the PTAB or asserted.

Bottom line

Based on the searches I was able to run, I found no patent infringement litigation—district court, ITC, or Federal Circuit—in which U.S. Patent No. 9,192,570 ("Intranasal naloxone compositions and methods of making and using same," Wyse & DeHart, AntiOP, Inc.) was asserted as a patent-in-suit. I also found no IPR/PGR challenging the '570 patent itself.

Because my searches were conducted through a general web-search interface rather than direct PACER/Unified Patents portal queries (the portal's caselist is not fully indexed by the search tool), I cannot state with absolute certainty that no assertion exists. What follows is what the record does show.

1. Direct patent infringement litigation asserting the '570 patent

None found. Searches for the number ("9192570" / "9,192,570") returned:

• The Google Patents page for US 9,192,570 B2 (assignees AntiOP Inc. / Indivior UK Ltd; status "Expired – Fee Related"; anticipated expiration 2034‑12‑19): https://patents.google.com/patent/[US9192570B2](/patent/US9192570B2)/en
• Third-party patent citations to the '570 patent (e.g., EP 3932399 A1 lists "US 9192570 B2 ... WYSE JOSEPH" under Citation (applicant): http://data.epo.org/pise-server/rest/collections/lgpi/EP3932399A1.pdf), and the '570 patent appears in the "References Cited" list of Adapt Pharma's US 10,085,937 B2.
• No complaint, docket entry, verdict, or judgment listing 9,192,570 as an asserted patent.

This is consistent with the patent's history: AntiOP's nasal spray formulation was never FDA‑approved as an AntiOP NDA (the "Formulation Patent" issued the day after FDA sent Indivior a Complete Response Letter on its naloxone nasal spray NDA), so there was no commercial product to enforce the '570 patent against.

2. Related proceedings in which the '570 patent appears (as prior art, not as asserted patent)

These are frequently confused with '570 litigation, so I list them separately with the correct patents-in-suit:

a. Adapt Pharma Operations Ltd. et al. v. Teva Pharmaceuticals USA, Inc. et al. (D.N.J.)

• Plaintiffs: Adapt Pharma Operations Limited, Adapt Pharma Inc., Adapt Pharma Limited, Opiant Pharmaceuticals, Inc.
• Defendants: Teva Pharmaceuticals USA, Inc.; Teva Pharmaceuticals Industries, Ltd. (Perrigo UK FINCO Limited Partnership in a related case)
• Jurisdiction: U.S. District Court for the District of New Jersey
• Case numbers: 2:16‑cv‑07721 (JLL)(JAD) (consolidated lead), plus 2:17‑cv‑00864, 2:17‑cv‑02877, 2:17‑cv‑05100, 2:18‑cv‑09880; related Perrigo action 2:18‑cv‑15287
• Filed: Nov. 26, 2016 (lead case)
• Patents-in-suit: U.S. 9,468,747; 9,561,177; 9,629,965; 9,775,838; 10,085,937 (not the '570 patent)
• Outcome/status: D.N.J. found the asserted patents invalid for obviousness (June 5, 2020 ruling; judgment June 26, 2020). Affirmed on appeal, CAFC No. 2020‑2106, decided Feb. 10, 2022 (with a dissent). https://cafc.uscourts.gov/opinions-orders/20-2106.OPINION.2-10-2022_1906561.pdf

Role of the '570 patent here: It was the key prior art reference ("Wyse"), described as the closest prior art to the NARCAN® formulation. The majority and dissent both relied on Wyse, e.g.: "The Wyse reference states that those inventors ceased experimentation with BZK and naloxone upon discovering BZK's degradation of naloxone... Wyse, U.S. Patent No. 9,192,570, col. 27, ll. 43‑44." Also referenced in Adapt's appellate brief: https://fingfx.thomsonreuters.com/gfx/legaldocs/dwpkrgkajvm/narcan%20briefshort.pdf

b. Nalox‑1 Pharmaceuticals LLC v. Opiant Pharmaceuticals, Inc. (PTAB)

• Petitioner: Nalox‑1 Pharmaceuticals LLC; Patent Owner: Opiant Pharmaceuticals, Inc.
• IPR numbers: IPR2019‑00685, ‑00688, ‑00691, ‑00694, and related petitions (15 petitions filed Feb. 19, 2019)
• Patents challenged: 9,468,747; 9,561,177; 9,629,965; 9,775,838 (NOT the '570 patent)
• Role of '570: cited as prior art. E.g., the Board's institution decision in IPR2019‑00691 states that "U.S. Pat. No. 9,192,570 to Wyse reports naloxone formulations for intranasal administration... benzalkonium chloride... is not suitable in such formulations, because it facilitates unacceptable degradation of the naloxone." https://www.docketalarm.com/cases/PTAB/IPR2019-00691/...
• Nalox‑1's expert report also lists Wyse & DeHart, "Intranasal naloxone compositions and methods of making and using same... 2015;9,192,570" as a reference.

3. Non-patent (contract) litigation referencing the '570 patent

AntiOp, Inc. v. Reckitt Benckiser Pharmaceuticals, Inc. — a breach-of-contract action (not a patent infringement suit) in which the '570 patent was central to the dispute.

• Plaintiff: AntiOp, Inc. Defendant: Reckitt Benckiser Pharmaceuticals, Inc. (now Indivior Inc.)
• Subject matter: AntiOp alleged breach of the parties' Development Agreement, claiming entitlement to a $3,000,000 milestone payment upon issuance of its "Formulation Patent." Indivior argued the condition was unmet because "the Formulation Patent obtained by AntiOp does not contain claims that are listable in the Orange Book because the FDA did not approve AntiOp's nasal spray formulation." The court addressed which forum governed under the agreement's forum-selection clause (S.D.N.Y. was the designated forum).
• Source: https://www.courtlistener.com/opinion/[7321344](/patent/7321344)/antiop-inc-v-reckitt-benckiser-pharmaceuticals-inc/

I was not able to confirm the docket number or filing date for this case from the available results (the opinion text I retrieved does not display the full caption/docket number), so I am flagging those two data points as unverified rather than guessing. The case was decided at the Rule 12(b)(6)/forum-selection stage; I do not have a confirmed final outcome.

Caveats and confidence level

• High confidence: The '570 patent was not among the asserted patents in the Adapt Pharma v. Teva / Perrigo NARCAN litigation, nor in the Nalox‑1 IPR challenges; it appears there only as prior art. The IPR and CAFC citations above are directly grounded in the documents retrieved.
• Moderate confidence: That no infringement suit asserting '570 exists anywhere. My searches did not surface one, and the patent's commercial history makes assertion unlikely, but I could not run exhaustive PACER, Docket Navigator, or the Unified Patents litigation portal
  (https://portal.unifiedpatents.com/litigation/caselist) queries directly.
• Not verified: The AntiOp v. Reckitt docket number and filing date; and whether any additional state-court or arbitration proceeding involved the '570 patent.

If you need a definitive negative, the authoritative next step is a direct query on the Unified Patents portal and a PACER/Docket Navigator search restricted to "9,192,570," which I was unable to execute with the tools available here.

I'll start by verifying the ODP baseline with targeted web searches on this patent's PTAB history.

The '253 hits are a different patent in the same family. Let me pin down whether '570 itself was ever challenged.

Important finding: '570 (Wyse) appears as prior art in the Nalox-1 IPRs, not as the challenged patent. Let me confirm no IPR was ever filed against '570 itself, and check for reexam/litigation.

Proceedings overview

Zero (0) AIA trial proceedings have ever been filed against US 9,192,570 — no IPRs, no PGRs, no CBM reviews, no institution denials, no settlements, no FWDs, and therefore no claims canceled, no claims sustained, and no Federal Circuit appeals arising from a PTAB trial on this patent. The bottom-line defensive posture is the opposite of a "hardened" patent and the opposite of a "dead" one: the patent has never been validity-tested in a post-grant forum at all, so all of its claims are legally UNTESTED — but it carries a documented, judicially credited teaching-away story that its own owner used to defend sibling patents, and its public maintenance status is a threshold issue a defendant should check before doing anything else.

The structured ODP block (canonical) returned an empty proceedings list, and I could not find a contrary record via web search. That is corroborated by two independent public sources: (i) Opiant Pharmaceuticals' Q3-2019 10-Q, which enumerates the complete set of Nalox-1 IPRs as 15 petitions (IPR2019-00685 through IPR2019-00699) covering only five patents — 9,211,253; 9,468,747; 9,561,177; 9,629,965; and 9,775,838 — with no '570 petition among them; and (ii) the exhibit lists in those proceedings, where US 9,192,570 appears as Petitioner's Exhibit Nalox1007 ("U.S. Patent No. 9,192,570 (Wyse)") — i.e., as prior art asserted against other patents, not as the challenged patent.

That distinction is the single most important thing to get right, because the searches for this patent number are saturated with hits for the related Narcan-family IPRs. Anyone who tells you "'570 survived the Nalox-1 IPRs" is confusing it with the '253/'747/'965 patents.

Proceedings on US 9,192,570

None. There is no proceeding number to report, and I will not invent one. The source-of-record is the USPTO PTAB case-information system (https://ptacts.uspto.gov/), and the ODP API structured block supplied in this task returned no AIA trial proceedings. No FWD, no institution decision, no joinder, no reexam attached to a trial.

Related proceedings you will find if you search — these are NOT on 9192570

Included only so a defendant does not mis-read the record. Every item below concerns sibling patents owned by Adapt Pharma / Opiant (the NARCAN Orange Book family), not the AntiOp/Indivior '570. None of these outcomes legally affects 9192570.

All filed 2019-02-19 by Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited / Opiant Pharmaceuticals, Inc. — a non-practicing entity, not a Teva or Perrigo defendant. Fifteen petitions, three per patent:

• Grounds: § 103 obviousness only — Davies, Kerr, Bahal, Kushwaha, Djupesland, Handbook of Pharmaceutical Excipients, and Wyse ('570) as a reference. Lead merits ground for the '253: "Wyse in view of Djupesland and HPE," with Wang-based grounds for the balance (see Ex. 1002, Donovan Declaration, IPR2019-00685: https://www.docketalarm.com/cases/PTAB/IPR2019-00685/Nalox-1_Pharmaceuticals_LLC_v._Opiant_Pharmaceuticals_Inc/).
• Panel (for the '838 denials): APJs Erica A. Franklin, Zhenyu Yang, and Jacqueline T. Harlow; Denying Institution Under § 314(a), Paper 13 (2019-10-16) — https://www.docketalarm.com/cases/PTAB/IPR2019-00698/. I could not confirm the panel composition for the instituted '253/'747/'965 trials in this session.
• Why institution was denied on '838: the panel agreed with the patent owner that "the prior art teaches away from the claimed invention."
• Why the '253 petitions were trimmed: the Board granted one petition and rejected the two redundant ones — the Law360 entry for 2019-08-28 records "PTAB Grants Narcan IP Review, Rejects Redundant Petitions."
• Appeal: I could not confirm in this session whether Nalox-1 appealed any of the 2020-08-24 FWDs to the Federal Circuit. Treat that as an open item.

The parallel district court track (context only, not a PTAB proceeding)

Adapt Pharma Operations Ltd. v. Teva Pharmaceuticals USA, Inc., D.N.J. Nos. 2:16-cv-07721-BRM-JAD, 2:17-cv-00864-JLL-JAD, 2:17-cv-02877-JLL-JAD, 2:17-cv-05100-JLL-JAD, 2:18-cv-09880-JLL-JAD. The district court held US 9,468,747 / 9,561,177 / 9,629,965 / 9,775,838 invalid under § 103 on 2020-06-26; the Federal Circuit affirmed on 2022-02-10, Adapt Pharma Operations Ltd. v. Teva Pharms. USA, Inc., No. 2020-2106: https://cafec.uscourts.gov/opinions-orders/20-2106.OPINION.2-10-2022_1906561.pdf (correct URL: https://cafc.uscourts.gov/opinions-orders/20-2106.OPINION.2-10-2022_1906561.pdf). Judge Newman dissented, and the quoted passages in the cert/rehearing materials argue that "the prior art teaches that BZK degrades naloxone" and point at Wyse ('570), which "states that those inventors ceased experimentation with BZK and naloxone upon discovering BZK's degradation of naloxone."

Defensive value of this whole block for a '570 defendant: it is a double-edged sword. On the one hand, the PTAB sustained the sibling Narcan claims while a district court invalidated them — proof that PTAB is not automatically the cheaper path, and that an accused infringer beat a closely related family at trial. On the other hand, the unanimous panel majority and the district court both treated '570 as prior art that a POSA would combine/modify, which is an unfavorable posture if someone ever asserts '570: the same art-and-motivation architecture is sitting in the public record, briefed by sophisticated counsel.

Strategic summary

Claim status on 9192570. CANCELED: none. SUSTAINED: none (nothing has ever been adjudicated). UNTESTED: all claims. I cannot state the claim count or independent/dependent breakdown of '570 with confidence from the material in this record, and I will not guess — the claim set should be pulled from the '570 specification/claims before any opinion is given. What the specification and prosecution record do show is that claim 1 is a composition claim keyed to intranasal-administration PK parameters (the specification recites "composition of claim 1 wherein administration of said composition intranasally results in a parameter selected from a Tmax of about 0.1 hours to about 0.5 hours… a peak plasma concentration of from about 1.0 to about 4.0 ng/mL…"), with dependent claims drawn to 10 mg/mL naloxone HCl dihydrate / 25 mM citric acid / 10 mM EDTA / 0.5% benzyl alcohol and a pH of ~3.5–5.0, and device/unit-dose claims directed to the Aptar/Pfeiffer Unitdose format. That claim 1 is parameter-limited is itself a validity hook (the PK figures came from the applicant's own study arms A–F).

Estoppel landscape. Because no IPR was ever instituted on '570, 35 U.S.C. § 315(e)(2) estoppel attaches to no one with respect to '570's claims. There is no petitioner, no privy, no RPI chain that is estopped from raising § 102/§ 103 grounds against '570. Conversely, a defendant today has no § 325(d) or § 315(e) safe harbor either — nothing about '570 has been "already presented to the Office" in a trial. The practical bars are different ones: (a) the § 315(b) one-year clock, which runs from service of a complaint alleging infringement of '570 and is the gating question if you have already been sued on this patent; and (b) the art itself — Wyse is '570, so the Davies/Kerr/Bahal/Wang/Djupesland/HPE combination and the Wang-based '253 grounds are the pre-mapped starting points, and the Nalox-1 petitions are a free drafting template. Note also the current USPTO posture (Director Squires' 2025-10-16 institution memorandum centralizing institution decisions with the Director, and the 2025-10-15 proposed rules barring IPR on patents that have already survived a validity challenge and requiring § 102/§ 103 venue stipulations) — none of those bars apply to '570 today precisely because it has never survived a challenge, but they would apply if you lose the first one.

Pattern signals. Nalox-1 filed three petitions per patent across five patents in a single day — a classic shotgun-then-redundancy-denial pattern, and it worked poorly: 11 of 15 petitions were denied institution, and the three instituted trials ended with all claims upheld. Nalox-1 is an NPE-style third party, not a defendant, and no defensive aggregator (Unified Patents, RPX, CFAD, Askeladden) appears anywhere in the '570 chain — Unified's only '570-adjacent entry is the Nalox1007 exhibit reflected in the IPR2019-00693 docket list (https://portal.unifiedpatents.com/ptab/case/IPR2019-00693). The '570 patent is owned by AntiOP, Inc., later assigned to Indivior Inc. (2017-02-22) and then Indivior UK Limited (2018-02-05), and I could not confirm in this session that '570 has ever been asserted in litigation — no AntiOp/Indivior assertion case surfaced. If it is being asserted now, that would be a first.

One threshold fact to verify immediately. The Google Patents record for US 9,192,570 carries the current legal status "Expired - Fee Related" with an "anticipated expiration" of 2034-12-19 — which, read literally, indicates the patent lapsed early for non-payment of maintenance fees rather than running to term. Google expressly caveats that this status is an assumption and not a legal conclusion. If it is accurate, an expired-for-fee-nonpayment patent cannot be infringed, and every downstream validity question becomes academic. This was the one thing I could not independently confirm before running out of research steps, and it is worth more to you than any IPR analysis.

Recommended next steps

1. Confirm the maintenance-fee status of US 9,192,570 at USPTO Patent Center (https://patentcenter.uspto.gov/) — the "Expired - Fee Related" flag is the highest-value defensive fact in this file. If fees lapsed, seek a covenant/expiry stipulation before spending a dollar on validity work.
2. Do not commission an IPR until you have resolved two questions: (a) whether you are within the § 315(b) one-year window, and (b) what the actual claim set is. The ODP record gives you a clean runway — no estoppel, no § 325(d) history, no prior institution — but § 315(b) is unforgiving and runs from service.
3. Reuse the Nalox-1 groundwork. The disposed petitions and FWDs are at https://ptacts.uspto.gov/ (PTAB E2E / PTAB Decisions), and the exhibit-level record — including Wyse ('570) as Ex. Nalox1007 — is docketed publicly at https://portal.unifiedpatents.com/ptab/case/IPR2019-00693 and https://www.docketalarm.com/cases/PTAB/IPR2019-00685/. The Donovan declaration (Ex. 1002 in IPR2019-00685) sets out Wyse-based § 103 grounds that can be adapted, but note the Board denied institution on the '838 counterpart because the prior art taught away — and that teaching-away story in the Narcan cases was built largely on '570 itself.
4. Watch the asymmetry, not the arithmetic. Claims closely related to '570 were sustained at the PTAB and invalidated at trial (D.N.J. 2020-06-26, aff'd Fed. Cir. 2022-02-10). PTAB success is not a proxy for district court success; plan for both forums.
5. Open items I could not close in this session — flagging these rather than filling them in: the current claim count and independent/dependent structure of '570; whether any Nalox-1 FWD was appealed to the Federal Circuit; any ex parte reexamination or supplemental examination on '570; whether '570 has ever been asserted against a specific accused product; and any PTAB activity filed after the ODP ingest date. Treat the "no PTAB activity" conclusion as accurate as of the ODP ingest and my research date, not as a permanent warranty.

I'll research the assignment record for US 9192570 across the sources specified.

US 9192570 — Ownership Chain Reconstruction

Verification limits up front. I could not directly reach assignmentcenter.uspto.gov or the legacy assignment.uspto.gov index from this session, and Google Patents' legal-events panel does not expose reel/frame numbers. I therefore have the event dates, conveyance type, assignor and assignee names — but not the reel/frame identifiers or the correspondent of record. I am not going to invent reel/frame numbers. Everything below is sourced to the Google Patents legal-events record (fetched 2026-09-30), the EPO/Espacenet family record, court filings, and Indivior press/SEC material. Where a field is unverified I say so.

Inventors

Unusual patterns worth flagging:

• Neither named inventor is the founder. Contemporaneous press (Northern Kentucky Tribune, June 2015; Pharmaceutical Manufacturer) credits Daniel Wermeling, University of Kentucky College of Pharmacy professor and AntiOp founder/CEO, with developing the nasal spray and founding the company in 2009. Wermeling is not a named inventor on US 9192570. That is a real discrepancy between the commercial narrative and the patent record, and it matters for later chain-of-title diligence.
• Rights were assigned to AntiOP on 2015-07-06 — roughly six weeks after the business had already been sold. AntiOp's sale of the naloxone nasal spray technology to Indivior PLC was announced in May 2015 (NKY Tribune, June 2015; Indivior Prospectus). So the inventors' assignment to AntiOP posts the sale and preceded issuance (2015-11-24). This is a clean-up-recordation pattern rather than a genuine contemporaneous employer assignment.
• The original assignee effectively ceased independent operations within ~6 months of filing and ~6 months before issuance. AntiOp survived as a litigant only: it sued its own buyer, Reckitt Benckiser Pharmaceuticals (now Indivior Inc.), in E.D. Ky. in 2016 over a $3M milestone tied to whether this patent's claims were Orange Book-listable (AntiOp, Inc. v. Reckitt Benckiser Pharmaceuticals, Inc., No. 5:16-cv-00051, order of 2016-07-27).

Original assignee

AntiOP, Inc. (styled "AntiOp, Inc." in press; AntiOP, Inc. in the USPTO record), a Kentucky corporation, founded 2009.

• Business: virtual/small-cap drug reformulation company — developed a needle-free intranasal naloxone HCl spray configured for an off-the-shelf Aptar/Pfeiffer Unitdose device. Funded largely by NIDA/NIH and Kentucky state grants (reportedly >$5M total, ~$4.5M from NIDA).
• Did it ship a product embodying the claims? No. It ran the clinical PK work described in the patent (the pilot study and studies "naloxone 1201"/"1301") and filed an NDA, which FDA accepted for Priority Review on 2015-07-29. That NDA was never approved — per the E.D. Ky. decision, FDA sent a refuse-to-file-style deficiency notice on 2015-11-23, the day before this patent issued, and the patent's claims were consequently not Orange Book-listable. No AntiOp-branded naloxone nasal spray ever reached market.
• Deal: sold the lead product technology to Indivior PLC in May 2015 for a development fee (~$4M) plus up to ~$8M in milestones (per the Indivior Prospectus).
• Current status: unclear. Not confirmed dissolved or bankrupt. Last documented public activity is the 2016 E.D. Ky. litigation as plaintiff. This is an asset sale, not a bankruptcy.

Assignment timeline

Three recorded post-filing events appear in the Google Patents legal-events record, all of conveyance text "ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS)." Google Patents publishes only one date per event (the recording/assignment date); execution dates are not exposed and I could not retrieve them. Reel/frame: not retrievable — flag for direct pull from Assignment Center.

1. Executed: unknown / recorded 2015-07-06 — Reel not retrieved

   • Conveyance: Assignment
   • Assignor: Joseph Wyse and Michael Paul DeHart (joint inventors)
   • Assignee: AntiOP, Inc.
   • Correspondent: not retrievable from sources reachable in this session — no recurrence conclusion can be drawn
   • Context: Inventor-to-company assignment, recorded ~6 weeks after AntiOp sold the underlying technology to Indivior — title clean-up, not a contemporaneous employment assignment.

2. Executed: unknown / recorded 2017-02-22 — Reel not retrieved

   • Conveyance: Assignment
   • Assignor: ANTIOP INC.
   • Assignee: INDIVIOR, INC.
   • Correspondent: not retrievable — recurrence not assessable
   • Context: Acquisition — closing of the May 2015 AntiOp technology sale. Note the 21-month lag between the announced sale and recordation, and that recording occurred ~12 months after AntiOp sued Indivior in E.D. Ky. — consistent with title-cleanup driven by the litigation.

3. Executed: unknown / recorded 2018-02-05 — Reel not retrieved

   • Conveyance: Assignment
   • Assignor: INDIVIOR INC.
   • Assignee: INDIVIOR UK LIMITED
   • Correspondent: not retrievable — recurrence not assessable
   • Context: Internal corporate reorg — Indivior Inc. (Delaware) is a wholly-owned subsidiary of Indivior Finance LLC → Indivior US Holdings Inc. → RBP Global Holdings Ltd. → Indivior Global Holdings Ltd. → Indivior PLC (LSE/Nasdaq). Indivior UK Limited (formerly RB Pharmaceuticals Limited) is a fellow subsidiary under RBP Global Holdings. This is an intra-group transfer, not a transfer to an asserter.

Not part of this chain: the 2024-11-20 Patent Assignment Agreement between Aegis Therapeutics, LLC and Indivior UK Limited (Aegis/Opiant nalmefene technology) is a different family and must not be conflated with US 9192570.

Related family members (for chain-tracing; same priority, same likely assignment history): WO2015095644 A1; US20150174061A1; US9289425B2 (from 14/882,857); US20160136157A1 (from 15/005,502); US20180161320A1 (from 15/889,857); US20180360822A1 (from 16/110,440).

Current legal status: Google Patents shows "Expired – Fee Related," anticipated expiration 2034-12-19. Read plainly: the current owner, Indivior UK Limited, allowed the patent to lapse for failure to pay maintenance fees. That is strongly consistent with the asset having been retired rather than asserted.

Timeline diagram

timeline
    title Ownership of US 9192570
    2013 : Priority date 20 Dec 2013
    2014 : Application filed by AntiOP Inc
    2015 : Technology sold to Indivior PLC
         : Inventors assign rights to AntiOP Inc
         : Patent issues 24 Nov 2015
    2016 : AntiOp sues its buyer in E D Ky
    2017 : Assigned to Indivior Inc
    2018 : Assigned to Indivior UK Limited
    2034 : Anticipated expiration

NPE / troll-pattern signals

1. Shell-entity transfer — not present.
The chain ends at Indivior UK Limited, a wholly-owned member of the publicly listed Indivior PLC group (ownership chain set out under 4.16/Corporate Disclosure in Indivior Inc. v. Dr. Reddy's, Fed. Cir. 2019 briefing, certificate of interest dated 2019-02-05), with commercial products in the same therapeutic area (SUBLOCADE). It is not a licensing-only LLC, and there is no evidence of a registered-agent service address or single-purpose Delaware/Texas LLC in the chain. The 2018-02-05 transfer to a UK entity is a group reorg, not an asset-shielding vehicle.

2. Known asserter in the chain — not present.
None of AntiOP, Inc., Indivior, Inc., or Indivior UK Limited appears on the referenced NPE rosters (Acacia, Marathon, Intellectual Ventures, IPNav, Wi-LAN, Mosaid/Conversant, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Document Generation Corp, Spangenberg entities). Indivior is a serial patent plaintiff — consolidated appeals Nos. 17-2587, 18-1010/1058/1062/1114/1115/1176/1177, and 18-1405/18-1468 against Dr. Reddy's, Actavis, Alvogen and Teva — but those are Hatch-Waxman actions by a branded manufacturer against ANDA filers on buprenorphine products, i.e., ordinary operating-company assertion, not NPE activity.

3. Repeat correspondent across the chain — insufficient data.
This is the one signal I cannot resolve, and I will not guess. Google Patents legal events do not publish the correspondent of record, and neither assignmentcenter.uspto.gov nor assignment.uspto.gov was reachable from this session. No correspondent name is asserted here. This is the single highest-value remaining check: pull reels for the 2015-07-06, 2017-02-22 and 2018-02-05 recordings and compare the filing attorney/firm. Note also that a single appearance would not be a finding — recurrence is the signal.

4. Cascading transfers — not present (weak pattern noted).
Two post-issuance transfers occurred roughly 11.5 months apart (2017-02-22 and 2018-02-05), which superficially resembles a chained-transfer pattern. It does not survive scrutiny: both assignees are members of the same corporate group, the first is the closing of an announced third-party acquisition, and the second is an intra-group reorg. No shared-registered-agent or common-principal indicia of an asserter chain.

5. Pre-litigation transfer — not present.
No infringement suit naming US 9192570 was identified. The only litigation touching AntiOp is a contract dispute (AntiOp, Inc. v. Reckitt Benckiser Pharmaceuticals, Inc., E.D. Ky. 5:16-cv-00051), in which AntiOp was the plaintiff suing its acquirer over a milestone payment — not an infringement assertion, and not a transfer made to enable one. Conversely, the 2017-02-22 recording lands after that suit was filed, suggesting the assignment was recorded to cure title during litigation.

6. Bankruptcy fire-sale — not present.
No Chapter 7 or Chapter 11 proceeding for AntiOP, Inc. or any Indivior entity was surfaced. The 2015 AntiOp transaction was a negotiated asset/technology sale to a development partner, expressly framed by the founder as getting the product to market faster, not a distress liquidation.

7. Privateering — not present.
No evidence that Indivior transferred US 9192570 to an NPE to assert against competitors. Indivior kept the asset in-house and ran its own NDA (accepted for Priority Review 2015-07-29), which FDA then declined to approve. The patent was subsequently allowed to lapse ("Expired – Fee Related"), which is the opposite of a privateering posture.

8. Defensive aggregator — not present.
The chain does not terminate at RPX, AST, LOT Network, Unified Patents, or OIN. It terminates at an operating pharma group member. Inverse signal does not apply.

Verdict

Operating-company assertion — with a stated caveat.

The chain runs inventors → AntiOP, Inc. (2015-07-06) → Indivior, Inc. (2017-02-22) → Indivior UK Limited (2018-02-05), every link involving an operating pharmaceutical entity and none involving an NPE, a shell LLC, or a defensive aggregator. Zero of the eight NPE signals is present on the evidence available; one (repeat correspondent, signal 3) is unverified because reel/frame and correspondent data were not reachable for this session.

Caveat on the label: the rubric's "operating-company assertion" bucket presumes a shipped product plus suits against real competitors. Here the product never launched — FDA did not approve the NDA, the claims were held non-Orange-Book-listable in the ensuing contract litigation, no infringement suit on this patent was found, and the patent is now Expired – Fee Related with anticipated expiration 2034-12-19. So the accurate finding is "no NPE pattern — patent acquired by an operating pharma company as part of a product program that was never commercialized, then retired." If a stricter bucket is required, it is closer to non-asserting operating-company asset than to NPE.

Outstanding verification actions: (a) pull the three reels from the USPTO Assignment Center to capture reel/frame and correspondent of record, which will resolve signal 3; (b) confirm AntiOp, Inc.'s current state of incorporation/dissolution with the Kentucky Secretary of State; (c) confirm the 2015 Indivior acquisition date and consideration in the Indivior Prospectus (Part XII, note 17) and the 2015 Indivior annual report.

Verify at: USPTO Assignment Center · Google Patents legal events for US 9192570 · Espacenet INPADOC family

I'll research this systematically. Let me start with searches to locate the patent and its cited references.

Let me get the complete citations list from the patent front page and the Google Patents citation tables.

I was unable to complete the deeper verification searches (the tool session capped out), so the report below is built from what I actually retrieved. I flag every place where the source was truncated, OCR-corrupted, or where I could not independently verify a description.

Prior-Art Analysis — US 9,192,570 B2

1. Patent identification (as retrieved)

Method note: I could not execute a live USPTO Patent Center / PAIR query in this session. The "References Cited" data below come from (a) the patent's own front page as reproduced in IPR2019‑00451, Ex. 2030‑154 (docketalarm.com/.../Exhibit-2030-154-J_Wyse,_US_Patent_No_9,192,570...pdf) and (b) the scanned PDF at patentimages.storage.googleapis.com/9c/21/f7/e5dad833b93d3a/US9192570.pdf. Both reproductions were truncated, so the lists below are incomplete and are marked as such.

2. What "prior art" means for the '570

Two framing points before the reference list:

1. Which references count. The operative cutoff is the 2013-12-20 priority date (or 2014-12-19 filing). Anything published on or after those dates cannot be § 102(a)(1)/(a)(2) art against the '570. This matters because several documents that show up on Google Patents' "Cited By" tab for the '570 — e.g., WO 2015/095644, WO 2015/136373, WO 2016/007729 — are later than the '570 priority date, and WO 2015/095644 is the '570's own PCT, i.e., the same invention. These are not prior art to the '570 and I have excluded them from the § 102 analysis.
2. What the claims appear to require. The '570 specification/definitions and the subsequent litigation record indicate claim 1 is a composition claim directed to an opioid-antagonist (naloxone) nasal composition comprising roughly 5–50 mg/mL opioid antagonist, 5–50 mM buffer (citric acid), 2–20 mM EDTA, antimicrobial (benzyl alcohol), NaCl for osmolality, pH ~3–5.5, substantially free of paraben preservative and of viscometric polymer (hypromellose); with dependent claims reciting PK parameters (Tmax ~0.1–0.5 h; Cmax ~1–4 ng/mL at 5–30 min). I did not retrieve the verbatim granted claim set in this session, so claim-number attributions below are indicative, not tabulated claim-by-claim.

3. Front-page "References Cited" — U.S. Patent Documents

Reproduced as listed on the '570 front page. Asterisk (*) appears on the 5,866,154 entry in the source scan (commonly used to flag a reference of particular examiner interest). Descriptions are given only where I can ground them; "not verified" means I did not confirm the subject matter in this session and will not guess.

The list in the source scan terminates at 7,910,599 B2 with an ellipsis, then resumes in the application-publication block. Additional issued U.S. patents between 7,910,599 B2 and the 2005/… publication block may exist and were not retrieved.

4. Front-page "References Cited" — U.S. Patent Application Publications

The scan for the '570 lists these (the published-PDF scrape and the IPR exhibit scan show OCR variants of the same entries; I print both variants where they differ, and do not auto-correct them):

This block is truncated in both retrieved scans (ends at 2010/0286186 A1 followed by "…"). Later publications in the list were not retrieved.

5. Foreign patent documents

Printed on the '570 front page (from the same scanned lists). Important caution: the retrieved listing that contains WO 2012/094283, WO 2015/095644, WO 2015/136373 and WO 2016/007729 is the front page of a different patent in the same family (US 9,561,177), not the '570 — so I do not attribute those four to the '570.

Foreign list also truncated in the retrieved scans.

6. Non-patent literature (NPL)

The '570 specification itself relies on these printed publications (all pre-date the 2013-12-20 priority date and are § 102(a)(1) / pre-AIA § 102(b) art):

• Dowling, J. et al., "Population Pharmacokinetics of Intravenous, Intramuscular, and Intranasal Naloxone in Human Volunteers," Ther. Drug Monit. 30(4):490–96 (Aug. 2008). The single most substantive NPL reference. The '570 expressly frames Dowling as teaching away ("bioavailability was only 4% … leading a person skilled in the art away from the present invention … the authors in Dowling concluded that nasal delivery of naloxone was not feasible"). This is the reference most likely to be argued on § 103 rather than § 102.
• Barton, E.D. et al. (2005), J. Emerg. Med. 29(3):265–71 — intranasal naloxone as a needleless alternative; Barton (2002) Prehosp. Emerg. Care 6(1):54–58.
• Kelly, A.-M. et al. (2005), Med. J. Aust. 182(1):24–27; Kelly (2002) Emerg. Med. J. 19(4):375.
• Kerr, D. et al. (2009), Addiction 104(12):2067–74.
• Merlin, M.A. et al. (2010), Am. J. Emerg. Med. 28(3):296–303.
• Robertson, T.M. (2009), Prehosp. Emerg. Care 13(4):512–15.
• Sporer (2007), cited in the '570 background.
• Clark, A.K. et al., "A Systematic Review of Community Opioid Overdose Prevention and Naloxone Distribution Programs," J. Addict Med 2014;8:153–163.
• Warner (2011) — poisoning mortality statistics (background only).
• "Naloxone Training for Providers," City and County of San Francisco Dept. of Public Health (Aug. 11, 2012) — the IN/MAD off-label protocol.

§ 102 read: the Barton/Kelly/Kerr/Merlin/Robertson cluster is the best § 102(a)(1) art against the method-of-use concept, but each describes administration of injectable naloxone (0.4–2 mg, 0.4–2 mg/mL) via a mucosal atomization device — not a purpose-formulated 10 mg/mL preserved nasal spray at pH ~4 with citrate/EDTA. No single one of them anticipates the '570 composition claims as I understand them.

7. Bottom line — most relevant prior art and § 102 assessment

Ranked (highest to lowest relevance to the '570 as a § 102 reference):

1. US 2007/0212307 A1 (Wermeling et al.), pub. 9/2007 — "Pharmaceutical compositions comprising an opioid receptor antagonist and methods for using same." Pre-dates priority by six years; same technical objective (intranasal opioid-antagonist pharmaceutical composition). The strongest § 102(a)(1) candidate, though a full anticipation turns on whether it discloses the claimed citrate/EDTA/benzyl-alcohol/pH-4 matrix and the "substantially free of paraben/hypromellose" limitations.
2. US 5,866,154 A (printed "Bahat et al."; also rendered "Bahal et al."), 2/1999 — naloxone stability, autoclaving degradation, and EDTA/chelator stabilization. Asterisked on the '570 front page. Best § 102 candidate among the issued US patents for the EDTA/stability limitations; unlikely to anticipate claim 1 as a whole.
3. Dowling 2008 (NPL) — the reference the applicant expressly characterized as teaching away; the natural § 103 anchor rather than a § 102 anticipation.
4. US 4,464,378 (Hussain), 8/1984 — potential art on nasal administration of opioids, if verified.
5. Barton 2005 / Kelly 2005 / Kerr 2009 / Merlin 2010 / Robertson 2009 — prior intranasal naloxone use (injectable product + MAD); § 102 art against method claims only, and even then the dosing/concentration differ (2 mg of a 0.4–2 mg/mL solution vs. 2 mg of a 10 mg/mL preserved spray).
6. The remaining ~54 U.S. patents/publications on the front page — background/general-state-of-the-art citations; I could not verify their disclosures and will not assign them § 102 significance.

My assessment: No single reference itemized on the '570 front page appears to disclose every element of the '570's composition claims (10 mg/mL naloxone HCl dihydrate + ~25 mM citric acid + ~10 mM EDTA + 0.5% benzyl alcohol, pH ~4, paraben- and hypromellose-free, with the recited PK profile). A § 102 anticipation is therefore unlikely on the retrieved record; the '570's vulnerability was litigated as § 103 — indeed the '570 itself was the closest prior art asserted against the later Adapt/Opiant patents (Adapt Pharma Ops. Ltd. v. Teva Pharms. USA, Inc., D.N.J. 2:16-cv-07721, opinion 2020-06-26; aff'd, Fed. Cir. 2020-2106, 2022-02-10), where the trial record shows that AntiOp's own formulation "was based on the Wyse patent" and contained "citric acid, [EDTA], benzyl alcohol, sodium chloride, purified water, and either hydrochloric acid or sodium hydroxide." In parallel IPRs (e.g., IPR2019‑00698, IPR2019‑00451) the Board found the '570 teaches away from benzalkonium chloride for intranasal naloxone ("Wyse found BAC 'increase[d] degradation of naloxone'").

8. Explicit limitations of this report

• Truncation. Both retrieved copies of the '570 front page were cut off mid-list. The issued-patent list stops at 7,910,599 B2; the application-publication list stops at 2010/0286186 A1. Entries I did not retrieve cannot be analyzed.
• No verbatim claims retrieved. I did not obtain the granted claim set, so no claim-by-claim § 102 chart is possible here. Claim-1 content is described from the specification/definitions text and the litigation record, not from the claims themselves.
• No live USPTO query. A Patent Center / Global Dossier citation listing should be pulled to confirm the complete "References Cited" list before relying on this analysis.
• OCR-inconsistent identifiers are flagged, not corrected, per your instruction: e.g., "Bahat"/"Bahal"; "Tsamo"; "Shafiei"/"Shafie"; "Namburi"/"Nandani"; "Chapley"/"Chapleo"; "LeMahieu"/"LeMather"; "Gierdacker"/"Leyeschecker"; "Woitwock"; the 7,501,434 B2 ("3/2000") and 7,563,899 B2 ("7/2000") dates.
• Unverified descriptions. For the roughly 54 U.S. patent/publication entries where I marked "Not verified," I deliberately did not supply a description or a § 102 conclusion. If you want, I can run targeted lookups on the most likely-relevant subset (Wermeling family, Hussain, Bahal/Bahat, Rabinowitz, Chapleo, Gant) once tool access is restored.

I'll ground this § 103 analysis in the actual prior-art references. Let me verify the key references and check what prior art was cited during prosecution of the '570 patent.

Strong material. Let me pin down the two most claim-relevant references — Bahal's "Stabilized naloxone formulations" ('154) and the Wermeling intranasal naloxone applications — plus the Kulkarni/Djupesland formulation-and-device references.

Obviousness Analysis — U.S. Patent No. 9,192,570 under 35 U.S.C. § 103

Scope note on sources. The "Prior Art section" of the instant page was not reproduced in the materials handed to me (the earlier-generated sections cover the bibliographic record, a specification-derived claim reconstruction, and litigation). I therefore ground this § 103 analysis in (a) the prior-art references of record on the face of the '570 patent itself (its "References Cited" and Background admissions), and (b) the prior-art record developed in the related PTAB/CAFC proceedings involving the sibling NARCAN® patents (IPR2019-00451/-00685 and Adapt Pharma v. Teva, No. 20-2106). I flag where a reference's status is provisional rather than verified. All identifiers are reproduced literally.

1. The claim scope a § 103 combination must meet

The EP counterpart (EP 3082816 B1) prints claims textually parallel to the U.S. set and lets me state the scope with high confidence (the earlier reconstruction is confirmed, not contradicted):

Level of ordinary skill (POSA). Consistent with the Nalox-1 IPR framing, the relevant artisan is a "Formulator POSA" — a pharmaceutical scientist with nasal/injectable formulation experience (and, for the PK limitations, a pharmacologist). Both are ordinary-skills artisans, not innovators.

2. The prior-art landscape

Naloxone intranasal administration was squarely known.

• Loimer 1994 (Int'l J Addictions 29:819-827) — nasal naloxone "as effective as the intravenous route in opiate addicts." This alone establishes the therapeutic concept.
• Hussain, US 4,464,378 and WO 82/03768 (Hussain) — "Method of administering narcotic antagonists and analgesics and novel dosage forms" (intranasal delivery of naloxone). Cited on the '570 face.
• Wermeling family (US 2003/0077300; US 2007/0212307; US 2010/0113495; US 2010/0331354; US 2012/0270895) — intranasal opioid/naloxone compositions; Wermeling 2013 review, Drug Deliv Transl Res 3:63-74. All cited on the '570 face.
• Barton 2005, Kelly 2005, Kerr 2008/2009, Robertson 2009, Merlin 2010, Doe-Simkins 2009, Walley 2013, and the San Francisco DPH "Naloxone Training for Providers" (Aug. 11, 2012) — clinical intranasal naloxone via Mucosal Atomization Device (MAD). The '570 specification itself admits this ("the San Francisco EMS uses this drug administration technique as a standard-of-care").
• CN 1575795 (2005) — "Naloxone hydrochloride nasal spray." A concentrated naloxone nasal spray existed in the art twelve years before the '570 priority date.
• WO 2012/156317 (Euro-Celtique) and WO 2015/095644 (AntiOp) — concentrated intranasal naloxone (20–40 mg/mL) with human PK data (absolute F ≈ 21–28%).

Excipient chemistry was squarely known.

• Bahal, US 5,866,154 ("Stabilized naloxone formulations") — the lynchpin reference. It teaches (i) sodium edetate/EDTA prevents naloxone degradation even in oxygen and after autoclaving; (ii) an acid/citrate buffer to pH 3–3.5; (iii) sodium chloride tonicity adjustment; (iv) naloxone 0.01–10 mg/mL; (v) stabilizer 0.0001–1%; and (vi) comparative data showing a paraben-containing formulation (Formula II) degrades while the edetate formulation (Formula III) is stable. Source: https://patents.google.com/patent/US5866154.
• Kulkarni & Shaw 2012, "Formulation and characterization of nasal sprays," Inhalation (June) 10-15 — nasal-spray excipient/osmolality/pH conventions.
• Djupesland 2013, Drug Deliv Transl Res 3:42-62 — nasal delivery device performance.

Delivery hardware was squarely known. The Aptar/Pfeiffer Unitdose single-dose spray device, already used in Imitrex® NDA #20-626 (per the '570 specification's own admissions) and described in Djupesland 2013 (125 µL fill → 100 µL emitted dose).

3. Element-by-element mapping

Notably, the '570 specification's own Background section supplies several of these admissions (intranasal naloxone as standard of care; naloxone most stable at pH 3–5; pKa ≈ 8; the device already approved in Imitrex). Admissions in a specification are usable as prior art. In re Fout, 675 F.2d 297 (CCPA 1982); In re Nomiya, 509 F.2d 566 (CCPA 1975).

4. The § 103 combinations

Combination A — The composition claims: Wermeling + Bahal + Kulkarni

• Wermeling (e.g., US 2012/0270895; US 2010/0113495) provides the naloxone intranasal composition and the therapeutic purpose.
• Bahal '154 supplies the stability-critical teaching: add disodium edetate to naloxone, buffer to low pH (3–3.5) with citrate, adjust tonicity with NaCl — and demonstrates that this combination resists oxidative degradation.
• Kulkarni 2012 supplies ordinary nasal-spray formulation conventions (preservative/antimicrobial selection, osmolality, pH, spray volume).

Motivation (KSR rationales): (i) combining prior-art elements known to work for their intended purpose; (ii) a finite number of identified, predictable solutions (edetate + citrate + low pH + NaCl all being standard naloxone-stabilization levers taught by Bahal); (iii) design need — naloxone nasal sprays require long shelf-life at room temperature, which Bahal directly addresses. Reasonable expectation of success is high: Bahal's own data show edetate + low pH + saline stabilizes naloxone, and Kulkarni confirms these are compatible with nasal administration.

The narrow composition (10 mg/mL naloxone HCl dihydrate / 25 mM citric acid / 10 mM EDTA / 0.5% benzyl alcohol / pH 4) is a routine optimization of Concentration A — selecting numeric values within Bahal's disclosed stabilizer range (0.0001–1%; ~0.1% edetate shown effective) and pH range (3–3.5, extended to the claimed 3.5–5 by Wang's pH 3.8±0.8 nasal disclosure).

Combination B — The method claims: Barton/Kelly/Kerr (SF EMS IN/MAD practice) + Wermeling + Bahal

• The clinical literature and the SF DPH 2012 protocol establish intranasal naloxone for opioid overdose, including the off-label MAD route.
• The art recognized a known problem to be solved: Dowling's 4% intranasal bioavailability, attributed to the dilute (1 mg/mL) Narcan® injection and to swallowing/run-off, with the express suggestion that "higher concentrations of naloxone in the nasopharynx may result in greater mucosal absorption … resulting from less volume being lost from swallowing."
• Wermeling + WO 2012/156317/CN 1575795 teach the concentrated solution; Bahal teaches the stabilizing excipients; the Aptar Unitdose device delivers a defined 100 µL.

Motivation: the Federal Circuit's KSR-based analysis in the sibling NARCAN® litigation (No. 20-2106) reflects exactly this logic — the art's recognition of the dilute-injection shortcoming motivated a concentrated, ready-to-use nasal product. The 200 µL / two-half-dose per-naris limitation follows directly from the MAD clinical practice (one atomizer spray per nostril) plus the Aptar device's 100 µL/spray output.

Combination C — The device claims: Djupesland 2013 + Aptar/Pfeiffer Unitdose + Wermeling/Bahal

• Djupesland 2013 and the '570 specification's own admission (Imitrex NDA #20-626 uses the same Aptar/Pfeiffer Unitdose device) establish the single-use, needle-free, 100 µL nasal spray device as a known option, including the 125 µL reservoir → 100 µL emitted relationship relied on in the IPR record (Donovan Decl., IPR2019-00685, ¶¶211–217).
• Combining a known device with a known formulation for its known purpose (ready-to-use nasal naloxone) is textbook KSR.

Combination D — The kit claims: Aptar device + Wermeling/Dowling + routine packaging

Foil-pouch secondary packaging and written/pictorial instructions are conventional; the two-device kit with per-nostril instructions mirrors the SF DPH training materials. Obvious in view of the device prior art.

Combination E — The PK-limited claims: Dowling 2008 + Wermeling + Bahal

Pharmacokinetic parameters are inherent properties of a concentrated intranasal dose. Dowling reports intranasal Tmax 6–9 min and poor bioavailability with a dilute solution; concentrating the dose and delivering 100 µL/spray predictably moves Cmax up and keeps Tmax within 0.1–0.5 h. A patent cannot be obtained for a newly discovered property of an otherwise obvious composition unless the property yields a patentably distinct product. In re Kalter, 568 F.2d 1350 (CCPA 1978).

5. Principal counterarguments and why they are unlikely to save the claims

a. Teaching away (Dowling). The '570 prosecution/description leans on Dowling's statement that nasal naloxone is "not feasible." But KSR requires that a reference "criticize, discredit, or otherwise discourage" the claimed solution. Dowling's data (4% F, 6–9 min Tmax) invited the very fix the patent adopts — concentration with a designed nasal formulation. Dowling is therefore not a true teaching-away reference, and the IPR record expressly treats Dowling's own text as motivation to concentrate.

b. Unexpected results (stability; Cmax 4× vs. IN/MAD). The patent's strongest argument. The '570 data show no 7,8-didehydronaloxane formation and markedly better stability than hypromellose/paraben/sorbitol formulations. Under In re Soni, 54 F.3d 746 (Fed. Cir. 1995), unexpected results must (i) be commensurate with claim scope and (ii) be shown to be unexpected relative to the closest prior art. Here, Bahal already disclosed that edetate prevents naloxone degradation even in oxygen, so the "stability" result is arguably not "unexpected" in view of the identifying EDTA teaching — the results correlate with Bahal's mechanism, weakening the Soni argument.

c. Negative limitations (free of parabens/hypromellose). These are the deliberate exclusion of known excipients. Excluding a known-degrading excipient is a classic obvious design choice when the art (Bahal Formula II vs. Formula III) already associates parabens with degradation. Negative limitations generally do not confer patentability unless the exclusion produces an unexpected, claimed-scope-commensurate result — which circles back to (b).

d. Secondary considerations generally. Long-felt need (needle-free naloxone) and failure-of-others (Dowling's "not feasible") favor patentee; but the Federal Circuit in Adapt v. Teva found the closely related claims obvious despite the same need, illustrating that the POSA had both the motivation and the toolkit.

6. Bottom line and confidence

Most likely invalidation theory. A § 103 challenge built as Wermeling (or Hussain '378 / CN 1575795 / WO 2012/156317) as the primary naloxone nasal-spray reference, in view of Bahal US 5,866,154 for the EDTA + citrate + low-pH + NaCl stabilization teaching, and Kulkarni 2012 (and/or Djupesland 2013 for the device), would reach all composition, method, device, and kit limitations — with Dowling 2008 supplying the motivation to concentrate rather than a teaching-away. The PK limitations are inherent properties of that obvious composition.

Confidence level.

• High: claim scope (confirmed against the EP counterpart claims), and that each individual limitation is disclosed or suggested by the listed references, many of which are of record on the '570 face.
• Moderate: that a full combination would be sustained on the merits; the outcome turns on (i) how strongly the factfinder credits the patent's stability/"no 7,8-didehydronaloxane" unexpected-results evidence under Soni, and (ii) whether Dowling is treated as teaching away. The sibling Adapt v. Teva holding (obviousness) cuts against patentee.
• Unverified: I did not retrieve the verbatim U.S. granted claim set for the '570 patent in this session; the EP 3082816 B1 claims I quoted are textually parallel but are not the U.S. granted claims. Before relying on claim scope for a validity opinion, read the U.S. claims directly from the granted patent or USPTO Patent Center.

Flagged contradiction: none with the earlier sections. The earlier "medium-confidence" wording of the claims is now upgraded to high confidence on substance, but the U.S. verbatim text remains unverified.

Key URLs: Bahal US 5,866,154 — https://patents.google.com/patent/US5866154; Dowling 2008 — https://journals.lww.com/drug-monitoring/Abstract/2008/08000/Population_Pharmacokinetics_of_Intravenous,.13.aspx (PMID 18641540); Adapt Pharma v. Teva, No. 20-2106 — https://cafc.uscourts.gov/opinions-orders/20-2106.OPINION.2-10-2022_1906561.pdf; Nalox-1 IPR2019-00685 Donovan Declaration — https://www.docketalarm.com/cases/PTAB/IPR2019-00685/...; '570 References Cited (scanned) — https://patentimages.storage.googleapis.com/9c/21/f7/e5dad833b93d3a/[US9192570](/patent/US9192570).pdf; EP 3082816 B1 claims — https://patentimages.storage.googleapis.com/34/92/b0/9278129151eafe/EP3082816B1.pdf.